Stempoint Capital »

Alkermes shares owned by Stempoint Capital

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by Stempoint Capital from 13F filings

Historical chart of Stempoint Capital investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by Stempoint Capital

Quarter filed Position value Share count Share price at filing
2024-09-30 $1.4M 49k 27.99

More positions owned by Stempoint Capital

Syndax Pharmaceuticals (SNDX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Merus N V (MRUS)
Arcutis Biotherapeutics (ARQT)
Amicus Therapeutics (FOLD)
Applied Therapeutics (APLT)
Bristol Myers Squibb (BMY)
Crinetics Pharmaceuticals In (CRNX)
Biohaven (BHVN)
Praxis Precision Medicines I Com New (PRAX)
Autolus Therapeutics Spon Ads (AUTL)
Incyte Corporation (INCY)
Denali Therapeutics (DNLI)
Day One Biopharmaceuticals I (DAWN)

View all positions for Stempoint Capital

Top funds holding Alkermes

BlackRock
BlackRock
Vanguard Group
T. Rowe Price Associates
State Street Corporation
Renaissance Technologies
Baker Bros. Advisors
Pacer Advisors
Geode Capital Management
Deep Track Capital
PRIMECAP Management Company
American Century Companies
Commodore Capital
Dimensional Fund Advisors
Armistice Capital

View all funds holding Alkermes